openPR Logo
Press release

Zanamivir Market Size, Trends, Growth Analysis, and Forecast | Valuates Reports

01-21-2025 02:07 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Valuates Reports

Zanamivir Market Size

The global market for Zanamivir was estimated to be worth US$ 10 million in 2023 and is forecast to a readjusted size of US$ 14 million by 2030 with a CAGR of 4.5% during the forecast period 2024-2030.

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-3U10467/Global_Zanamivir_Market_Insights_Forecast_to_2028

This report aims to provide a comprehensive presentation of the global market for Zanamivir, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Zanamivir by region & country, by Type, and by Application.

By Type
• Purity 97%
• Purity 98%
• Purity 99%

By Application
• Pharmaceutical
• Scientific Research

Key Companies
Merck, Tokyo Chemical Industry (TCI), DC Chemicals, Hairui Chemical, Key Organics, BioCrick, BLD Pharmatech, BOC Sciences, CSNpharm, Selleck Chemicals, Glentham Life Sciences

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-3U10467/global-zanamivir

Please reach us at sales@valuates.com

Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Zanamivir Market Size, Trends, Growth Analysis, and Forecast | Valuates Reports here

News-ID: 3825548 • Views:

More Releases from Valuates Reports

AI-Powered Pathology Market Size, Revenue Share, Insights & Future Outlook
AI-Powered Pathology Market Size The global market for AI-Powered Pathology was valued at US$ 184 million in the year 2023 and is projected to reach a revised size of US$ 382 million by 2030, growing at a CAGR of 11.7% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-33C18563/Global_AI_Powered_Pathology_Market_Research_Report_2024?utm_source=openpr&utm_medium=referral By Type • Automated Image Analysis • Disease Classification • Predictive Modeling By Application • Hospital • Diagnostic Centers • Laboratories & Research Institutes Key Companies Indica Labs, Aignostics, Deep Bio, Mindpeak, Paige AI, DoMore Diagnostics, Visiopharm, Sonrai Analytics, Stratipath,
AI In Clinical Trials Market Size, Revenue Share, Insights & Future Outlook
AI In Clinical Trials Market Size The global market for AI In Clinical Trials was valued at US$ 52.3 million in the year 2024 and is projected to reach a revised size of US$ 82.4 million by 2031, growing at a CAGR of 6.8% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-29K15279/Global_AI_In_Clinical_Trials_Market_Research_Report_2023?utm_source=openpr&utm_medium=referral By Type • Software • Service By Application • Pharmaceutical and Biotechnology Companies • Contract Research Organization Key Companies Intel, The International Business Machines Corporation(IBM), Koninklijke Philips N.V., ConcertAl, Saama Technologies LLC,
Forensic Accounting Services Market Size, Revenue Share, Insights & Future Outlo …
Forensic Accounting Services Market The global Forensic Accounting Services market was valued at US$ 19930 million in 2022 and is anticipated to reach US$ 31160 million by 2029, witnessing a CAGR of 7.7% during the forecast period 2023-2029. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1E9323/Global_Forensic_Accounting_Services_Market_Size_Status_and_Forecast_2022?utm_source=openpr&utm_medium=referral In general, forensic accounting services entail using the specialized expertise and investigative abilities that CPAs possess to gather, examine, and assess the evidence as well as to interpret and convey conclusions
Dental Anesthesia Market Size, Revenue Share, Insights & Future Outlook
Dental Anesthesia Market The global market for Dental Anesthesia was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-8V13175/Global_Dental_Anesthesia_Market_Research_Report_2023?utm_source=Openpr&utm_medium=Referral By Type • Articaine • Lidocaine • Mepivacaine • Bupivacaine • Prilocaine • Others By Application • Carpool/Cartridges • Ampoules • Vials Key Companies Laboratorios Inibsa, Pierre Pharma, Septodont, Laboratorios Normon, Primex Pharmaceuticals, ASPEN Group, 3M Company, Dentsply, Fresenius-Kabi The Dental Anesthesia Market is experiencing steady market growth as dental care

All 5 Releases


More Releases for Zanamivir

Influenza Medication Market Size, Share, and Forecast 2023-2028 - by Types (Zana …
The Global Influenza Medication Market Report 2023 by 𝐏𝐫𝐚𝐠𝐦𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 provides a comprehensive overview of the market's latest trends, size, regulations, key players, and strategies. The report offers valuable insights into the market's sales and revenue, product type, applications, regions, and leading players. It also covers key players and competitor analysis, providing a comprehensive understanding of the market's commercial landscape. The report is useful for gaining insights and understanding the
Best Report on Influenza Medication Market with Segment (Zanamivir, Oseltamivir …
Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza primarily occurs in winter.
Influenza Vaccine Market : New Study Offers Insights for 2019 | Zanamivir, Oselt …
Global Influenza Medication Market: Snapshot Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild. Seasonal outbreak of influenza
Influenza Drugs and Vaccines Trends, Status, Sales, Revenue, Price and Gross Mar …
Global Influenza Drugs and Vaccines Market: WiseGuyReports.com adds “Influenza Drugs and Vaccines Market 2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database. WiseGuyReports.Com Publish a New Market Research Report On – Executive Summary: A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Influenza Market on the basis of Segment Type
The Future Growth of Global Influenza Drugs and Vaccines Market - By Drugs (Zana …
"The Report Global Influenza Drugs and Vaccines Market - By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent) - Analysis By Region, By Country: Opportunities and Forecast (2016-2021) - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, U.K., Germany, France, China, India, Japan) provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" A comprehensive research report created through extensive
Global Zanamivir Market 2016 - GlaxoSmithKline, Simcere, Lunan Pharmaceutical
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor